The ATM facility provides IN8bio with a flexible but dilutive capital source to fund operations. Given the $5.1M quarterly cash burn and $21.9M cash balance (per the prior 10-Q), this $2.8M facility extends runway by only ~2 months. Monitor the pace of ATM sales and any subsequent 10-Q for cash burn updates. The stock is likely to trade under pressure from the overhang of potential continuous dilution.
Price Chart
Executive Summary
IN8bio filed a 424B5 prospectus supplement establishing an at-the-market (ATM) equity offering facility with JonesTrading to sell up to $2.8M of common stock. The filing confirms the company is tapping its $200M shelf registration to raise cash for clinical development and working capital, following a prior S-3/A that highlighted a $5.1M quarterly cash burn and an auditor going-concern qualification. For a $18M market cap clinical-stage biotech with no approved products, this ATM facility signals ongoing dilution risk and near-term cash needs.
Key Facts
- IN8bio entered into a Capital on Demand Sales Agreement with JonesTrading to sell up to $2,800,000 of common stock in at-the-market offerings.
- The offering is taken from the existing $200M shelf registration (S-3/A filed May 18, 2026).
- Proceeds will be used for clinical development, working capital, and general corporate purposes.
- Sales Agent compensation is 3.0% of gross proceeds; estimated total offering expenses are approximately $200,000.
- As of March 31, 2026, the company had 9,847,089 shares outstanding and 9,620,002 pre-funded warrants exercisable at $0.0001 per share.
- The company's auditor included a going-concern explanatory paragraph in the FY2025 financial statements.
- The company has already sold $3,113,883 of securities under General Instruction I.B.6 of Form S-3 in the prior 12 months.
Financial Impact
Up to $2.8M in gross proceeds from new common stock sales, with 3.0% agent commission and ~$200K in expenses. Potential dilution of up to ~15% of current shares outstanding at the May 29, 2026 closing price of $1.87.
Risk Factors
- Continuous dilution from ATM sales at or near current market prices.
- Limited runway extension (~2 months of cash burn) does not resolve the going-concern risk.
- Pre-funded warrants (9.6M shares at $0.0001) represent massive additional overhang if exercised.
- No committed equity or minimum offering amount — actual proceeds are uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-249564 |
| Document: 0001193125-26-249564-index-headers.html | 0001193125-26-249564 |
| Document: 0001193125-26-249564-index.html | 0001193125-26-249564 |
| Document: 0001193125-26-249564.txt | 0001193125-26-249564 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | Press Release | $1.54 $1.04 | ▼ −32.47% | ▼ −34.97% | $0.9655 (−37.31%) |
Jun 1, 2026 21w ago | 8-K | $1.73 $1.17 | ▲ +32.37% | ▲ +33.60% | $0.9655 (+44.19%) |
Jun 1, 2026 21w ago | 424B5 | $1.73 $1.17 | ▲ +32.37% | ▲ +33.60% | $0.9655 (+44.19%) |
May 18, 2026 23w ago | S-3/A | $1.45 $1.18 | ▲ +18.62% | ▲ +24.91% | $0.9655 (+33.41%) |
May 7, 2026 24w ago | 8-K | $1.58 $0.9601 | ▼ −39.23% | ▼ −44.07% | $0.9655 (−38.89%) |
Mar 26, 2026 30w ago | DEFA14A | $1.41 $1.51 | ▲ +7.09% | ▼ −8.97% | $0.9655 (−31.52%) |
Mar 12, 2026 32w ago | Press Release | $1.89 $1.44 | ▼ −23.81% | ▼ −35.42% | $0.9655 (−48.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers